The Cooper Companies(COO) - 2026 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Consolidated revenues were $1.024 billion, up 6.2% year-over-year and up 2.9% organically [11][22] - Non-GAAP earnings grew 20% to $1.10 per share, with free cash flow at $159 million [11][23] - Operating margins improved significantly, with a gross margin of 68.1% [22] Business Line Data and Key Metrics Changes - CooperVision reported revenue of $695 million, up 7.6% or 3.3% organically, with strong growth in daily silicone hydrogel lenses [11][12] - CooperSurgical delivered revenue of $329 million, up 3.3% or 2.2% organically, driven by strong performance in the fertility segment [11][18] - Daily silicone hydrogel lenses grew 7%, led by double-digit growth in MyDay [11][14] Market Data and Key Metrics Changes - The Americas grew 6%, while EMEA grew 4%, strengthening market positions [12] - Asia Pac declined 4%, primarily due to softness in Japan related to older hydrogel products [12][13] - The company is optimistic about returning to growth in Asia Pac by fiscal Q3 due to new product launches [13][36] Company Strategy and Development Direction - The company is focused on consistent market share gains, operational excellence, and disciplined capital allocation [7][9] - There is a commitment to investing in sales and marketing initiatives to support product launches and strategic initiatives [9][10] - The strategic review process is ongoing, with a focus on maximizing long-term shareholder value [10][88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong start to the fiscal year, with expectations for continued growth in earnings and free cash flow [7][9] - The company anticipates challenges in Asia Pac but expects to overcome them with new product launches and improved execution [36][80] - The fertility market is showing signs of recovery, with improving IVF cycles in the U.S. and Europe [19][104] Other Important Information - The company repurchased $92 million in stock during the quarter and reduced net debt to $2.4 billion [24] - Guidance for fiscal 2026 has been raised, with expected consolidated revenues of $4.3 billion to $4.35 billion [25][26] Q&A Session Summary Question: Can you reconcile the 10% calendar Q4 number versus the last few quarters? - The difference is attributed to shipment timing, with a weak November and December followed by a strong January [31] Question: How is the plan to return to above-market growth progressing? - The Americas and EMEA are performing well, but Asia Pac needs improvement, particularly in Japan [34][36] Question: What is the exposure to the Middle East and potential impacts from the war? - The Middle East accounts for about 2% of sales, and while it could impact fertility business, overall momentum remains positive [40][41] Question: How should we think about operating margins and tariffs? - Durable savings from synergies and disciplined expense management are expected to continue, with tariffs factored into guidance [42][44] Question: What is the status of supply dynamics and new contracts? - Supply constraints have been resolved, allowing for the winning of new contracts across all regions [68][70] Question: What are the dynamics in the fertility market? - The fertility market is stabilizing with improving IVF cycles and renewed interest in new technologies [104]